Launch price of new medicines dropped very slightly in 2025
Amid ongoing angst over prescription drug prices, a new analysis found the median net price for 202 newly…
Karnataka FDA to withdraw order on drug price chart | Bengaluru News
Bengaluru: Karnataka Food Safety and Drug Administration (FDA) is set to withdraw its order directing hospitals, healthcare institutions…
Cancer Drugs In India May Get 20-70% Cheaper As NPPA Approves Price-Cutting Move | India News
News india Cancer Drugs In India May Get 20-70% Cheaper As NPPA Approves Price-Cutting Move Last Updated:October 09,…
AHPI Advocates for Fair Drug Pricing Amid Supreme Court Scrutiny, ETHealthworld
New Delhi: The Association of Healthcare Providers of India (AHPI) has called for a balanced approach to pricing…
Supreme Court takes suo motu cognisance of access to life-saving medicines – Deccan Herald
Supreme Court takes suo motu cognisance of access to life-saving medicines Deccan HeraldSupreme Court initiates suo motu case on…
Sales from controversial U.S. drug discount program rose to $100B last year
Ed’s stories explore prescription drug pricing, affordability and access, as well issues surrounding patents, litigation, and legislation. He…
Colorado’s first-of-its-kind price cap on an Amgen drug blocked
Ed’s stories explore prescription drug pricing, affordability and access, as well issues surrounding patents, litigation, and legislation. He…
Capricor Therapeutics accuses Nippon Shinyaku of slow-walking Duchenne drug
Capricor Therapeutics accused Nippon Shinyaku and its U.S. subsidiary of failing to follow through on marketing plans for…
UK and US lock in pharmaceutical deal – POLITICO
In an announcement on Thursday, the government confirmed it had agreed a text with the U.S. that exempted…
How a 340B successor might arise from the drug price negotiations
The 340B drug discount program requires manufacturers to sell drugs to safety-net hospitals at deep discounts, so they…
Consumer group presses U.S. to authorize generic GLP-1s
Public Citizen petitioned the Trump administration to use a federal law to authorize generic competitors for GLP-1 drugs…
Mark Cuban tries to shake up biosimilar pricing with a version of J&J’s Stelara
In its latest bid to shake up the prescription drug market, the Mark Cuban Cost Plus Drug Company…